Ovarian Cancer Canada’s efforts to attract leading minds to the field of ovarian cancer research while providing necessary resources have grown Canada’s collaborative ovarian cancer research community.

Why Research with OCC

Diverse funding opportunities

Our research spans the ovarian cancer continuum; from discovery to survivorship, addressing prevention, diagnosis, and treatment. We're dedicated to studying social determinants of health, promoting equity, and securing funding for less common ovarian cancer types.

National platform

We convene a national, multidisciplinary, collaborative network of experts dedicated to ovarian cancer including clinicians, scientists, trainees, and patient partners, and provide diverse opportunities to share research findings and improve study recruitment.

Access to national scientific resources

We enable groundbreaking translational research on all types of ovarian cancer through investments in foundational resources such as the OCC Tissue Banking Network and OCC’s collection of high-fidelity research models.

Scientific resources

ENABLING TRANSLATIONAL RESEARCH THROUGH THE OVARIAN CANCER CANADA TISSUE BANKING NETWORK

The Ovarian Cancer Canada (OCC) Tissue Banking Network is a virtual network of biobanks which collect, store, and distribute biological samples (e.g., tumour tissue/cells, normal tissue/cells, blood) generously donated by individuals with ovarian cancer to enable ovarian cancer research in Canada and abroad.

OCC currently provides support to biobanks in five provinces: British Columbia, Saskatchewan, Ontario, Quebec, and Nova Scotia. In 2023, there were 50 peer-reviewed scientific publications on studies involving samples and/or data from the OCC Tissue Banking Network. These publications contribute to new knowledge in diverse areas such as genetic risk factors, rare ovarian cancers, omics, treatment resistance, prognostic factors, and novel treatment strategies.

Scientists interested in accessing human ovarian cancer biospecimens for their research are encouraged to contact the individual biobanks for more information.

BUILDING YOUR SCIENTIFIC TOOLBOX: OCC’S COLLECTION OF RESEARCH MODELS

Ovarian Cancer Canada is proud to make available to researchers the OvCAN Collection, which is a virtual collection of high-fidelity research models of ovarian cancer. The development and/or characterization of these models has been funded by OCC.

The purpose of the OvCAN Collection is to facilitate the creation and sharing of these gold standard models among the ovarian cancer research community, to enable and expedite high-quality research focused on improving ovarian cancer outcomes.

If you are interested in incorporating one of these models into your study, please contact the individual lab for more information.

RESEARCH POLICIES AND PROCESSES

RESEARCH SAFEGUARDING POLICY

The policy ensures all OCC research activities which receive full or partial federal research funding comply with the Government of Canada’s guidelines about the integrity and security of sensitive technology research. This includes diligence in identifying sensitive technology research areas, scrutinizing researcher affiliations, and adhering to attestation and validation requirements in grant applications.

Research Safeguarding Policy
Sensitive Technology Research Area Checklist, Declaration and Attestation Form

RESEARCH Conflict of interest AND CONFIDENTIALITY POLICY

This policy aims to ensure the integrity of OCC’s research funding process. Specifically, this policy aims to ensure:

  • The confidentiality of information submitted to OCC or shared among funding organizations; including all information and decisions about research funding applications submitted, collected, prepared or made in connection with OCC’s research funding program.
  • The effective management of Conflict of Interest of any participant in the research funding review process, so that OCC research funding decisions are fair, objective and free of actual, perceived or potential Conflict of Interest.

Research COI and Confidentiality Policy
Research Policy Declaration Form

EVALUATION CRITERIA

Standardized evaluation criteria and scoring rubrics are used by independent academic (clinical, scientific) and patient reviewers for all Ovarian Cancer Canada-led open funding competitions, to ensure fair and equitable assessment and selection of funding applications.

Academic reviewer scoring rubric

Patient reviewer scoring rubric

Our Current Funds and Awards

COLLABORATE WITH OUR NATIONAL PATIENT PARTNERS IN RESEARCH TEAM

ABOUT THE PROGRAM

OCC’s research is patient centred and we believe that clinical and scientific inquiry can be enhanced by the unique perspectives of those affected by the disease.

OCC’s Patient Partners in Research (PPiR) program was developed in 2020 to ensure the voices of those with lived experience are at the forefront of research. Members of the PPiR team include ovarian cancer patients, previvors, caregivers, or loved ones, each bringing their unique perspective and shared experience to inform research. Members were selected to ensure a diverse representation of ovarian cancer types, age, sexuality, cultural backgrounds, and geography.

For prospective collaborators

To learn more about our program and how to collaborate:

FAQ for prospective collaborators

Research Partner Agreement

Research Engagement Details

PPiR poster – CCOCR 2024

«

I was thrilled to learn that I won the Anita Unruh Prize. I am honoured by this recognition, and it will encourage me to continue doing my best to contribute to the ovarian cancer research community.

Qingchuan Zhao, 2022 Anita Unruh Prize recipient

OVARIAN CANCER CANADA APPLAUDS THE GOVERNMENT’S COMMITMENT TO WOMEN’S HEALTH

Canada’s ovarian cancer research community is pushing the boundaries of how research is conducted, and what is possible to achieve on an accelerated timeframe.

A STRATEGIC PARTNERSHIP OF $1.2M FOR OVARIAN CANCER TREATMENTS

Ovarian Cancer Canada (OCC) and the Cancer Research Society (CRS) jointly announce the launch of the “Bridging the Gap for Ovarian Cancer Treatments Grants Competition”.

CLINICAL TRIAL: TARGETING THE TARGETS

Two funded clinical trials, though different in their approach and focus, share a dedication to exploring innovative treatment pathways and a made-in-Canada pedigree.